222 related articles for article (PubMed ID: 36765089)
41. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
[TBL] [Abstract][Full Text] [Related]
42. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma.
Zomerman WW; Plasschaert SLA; Conroy S; Scherpen FJ; Meeuwsen-de Boer TGJ; Lourens HJ; Guerrero Llobet S; Smit MJ; Slagter-Menkema L; Seitz A; Gidding CEM; Hulleman E; Wesseling P; Meijer L; van Kempen LC; van den Berg A; Warmerdam DO; Kruyt FAE; Foijer F; van Vugt MATM; den Dunnen WFA; Hoving EW; Guryev V; de Bont ESJM; Bruggeman SWM
Cell Rep; 2018 Mar; 22(12):3206-3216. PubMed ID: 29562177
[TBL] [Abstract][Full Text] [Related]
43. Structure and mechanism of the human CTDNEP1-NEP1R1 membrane protein phosphatase complex necessary to maintain ER membrane morphology.
Gao S; Carrasquillo Rodríguez JW; Bahmanyar S; Airola MV
bioRxiv; 2023 Nov; ():. PubMed ID: 38045299
[TBL] [Abstract][Full Text] [Related]
44. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
46. Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia.
Alassiri AH; Alsufiani FM; Almutairi AA; Almohini IA; Aldosari MA; Essa MF
Neurosciences (Riyadh); 2020 Jul; 25(3):218-221. PubMed ID: 32683405
[TBL] [Abstract][Full Text] [Related]
47. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas.
Eberhart CG; Kratz JE; Schuster A; Goldthwaite P; Cohen KJ; Perlman EJ; Burger PC
Brain Pathol; 2002 Jan; 12(1):36-44. PubMed ID: 11770900
[TBL] [Abstract][Full Text] [Related]
48. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.
McCall TD; Pedone CA; Fults DW
Cancer Res; 2007 Jun; 67(11):5179-85. PubMed ID: 17545597
[TBL] [Abstract][Full Text] [Related]
49. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
[TBL] [Abstract][Full Text] [Related]
50. WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma.
Rogers HA; Sousa S; Salto C; Arenas E; Coyle B; Grundy RG
Br J Cancer; 2012 Sep; 107(7):1144-52. PubMed ID: 22929883
[TBL] [Abstract][Full Text] [Related]
51. Research Trends in C-Terminal Domain Nuclear Envelope Phosphatase 1.
Rallabandi HR; Choi H; Cha H; Kim YJ
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374122
[TBL] [Abstract][Full Text] [Related]
52. Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma.
Bigner SH; Vogelstein B
Brain Pathol; 1990 Sep; 1(1):12-8. PubMed ID: 1669688
[TBL] [Abstract][Full Text] [Related]
53. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.
Weeraratne SD; Amani V; Teider N; Pierre-Francois J; Winter D; Kye MJ; Sengupta S; Archer T; Remke M; Bai AH; Warren P; Pfister SM; Steen JA; Pomeroy SL; Cho YJ
Acta Neuropathol; 2012 Apr; 123(4):539-52. PubMed ID: 22402744
[TBL] [Abstract][Full Text] [Related]
54. Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition.
Graziani V; Garcia AR; Alcolado LS; Le Guennec A; Henriksson MA; Conte MR
Sci Rep; 2023 Jan; 13(1):1273. PubMed ID: 36690651
[TBL] [Abstract][Full Text] [Related]
55. Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
[TBL] [Abstract][Full Text] [Related]
56. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma.
Martell E; Kuzmychova H; Kaul E; Senthil H; Chowdhury SR; Morrison LC; Fresnoza A; Zagozewski J; Venugopal C; Anderson CM; Singh SK; Banerji V; Werbowetski-Ogilvie TE; Sharif T
Nat Commun; 2023 May; 14(1):2502. PubMed ID: 37130865
[TBL] [Abstract][Full Text] [Related]
57. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
58. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
[TBL] [Abstract][Full Text] [Related]
59. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts.
Bigner SH; Friedman HS; Vogelstein B; Oakes WJ; Bigner DD
Cancer Res; 1990 Apr; 50(8):2347-50. PubMed ID: 2180567
[TBL] [Abstract][Full Text] [Related]
60. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
